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S100A6 (Calcyclin) is a calcium-binding protein that has been implicated in a variety of biological functions as well as tumorigenesis.
The aim of our study was to investigate the involvement of S100A6 during prostate cancer development and progression. Using
immunohistochemistry, the expression of S100A6 was examined in benign (n¼ 66), premalignant (n¼ 10), malignant (n¼ 66) and
metastatic prostate (n¼ 5) tissues arranged in a tissue-microarray or whole sections as well as in prostate cancer cell lines. The
S100A6 immunostaining pattern in tissues was compared with that of cytokeratin 5 (a basal cell marker) and 18 (a benign luminal cell
marker). In all cases of benign epithelium, intense S100A6 expression was seen in the basal cell layer with absent staining in luminal
cells. In all cases of prostatic adenocarcinoma (matched), metastatic lesions and 3/10 high-grade prostatic intraepithelial neoplasia
lesions, an absence of S100A6 was seen. Western blotting and RT–PCR analysis of cell lines showed S100A6 expression to be
absent in LNCaP, LNCaP-LN3 and LNCaP-Pro5 but present in Du145, PC3, PC-3M and PC-3M-LN4. LNCaP cells treated with 5-
Azacytidine, caused re-expression of S100A6 mRNA. Sequencing of bisulphite modified DNA showed CpG methylation within the
S100A6 promoter region and exon 1 of LNCaP, LNCaP-LN3 and LNCaP-Pro5 cell lines but not in Du145 cells. Our data suggest
that loss of S100A6 protein expression is common in prostate cancer development and may occur at an early stage. The mechanism
of loss of expression may involve hypermethylation of CpG sites. The finding of intense S100A6 expression in the basal cells of benign
glands but loss of expression in cancer could be useful as a novel diagnostic marker for prostate cancer.
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Prostate cancer is among the most commonly diagnosed cancers in
men and has become the second most common cause of cancer-
related deaths (Greenlee et al, 2000; Gronberg, 2003). However, our
understanding of its aetiology is limited. Molecular genetic studies
have shown that the frequency of genetic alterations is low
compared with other common cancers. The most common
alterations identified are loss of Glutathione S transferase-pi
(GST-pi) and Annexin expression (Lee et al, 1994; Paweletz et al,
2000; Chetcuti et al, 2001). The frequencies of loss of expression of
GST-pi, Annexin I and II approach 100% in prostate cancer.
Calcium plays an important role in a number of physiological
processes, thus intracellular calcium levels must be carefully
regulated. There are three main families of calcium-binding
proteins, which are thought to regulate calcium levels (Schafer
and Heizmann, 1996; Hawkins et al, 2000; Michalak et al, 2002;
Donato, 2003). The first family includes the endoplasmic reticulum
calcium-binding proteins; the second family includes the Annexins
and the third family includes the S100 members. Members of the
S100 protein family have been implicated in a variety of cellular
activities such as protein phosphorylation, enzyme activities, cell
proliferation and differentiation, as well as in tumorigenesis
(Schafer and Heizmann, 1996; Heizmann et al, 2002; Donato,
2003). It has also been reported that proteins from two different
families may form heterodimer complexes, such as the interaction
between S100A6 and Annexin II and between S100B and S100A6
(Zeng et al, 1993, Kuo et al, 1997; Deloulme et al, 2000).
S100A6 was initially identified as an mRNA preferentially
expressed in proliferating rather than quiescent cells (Calabretta
et al, 1986). Subsequent studies showed that increased S100A6
expression is associated with the metastatic potential of human
melanoma cell lines and primary melanomas (Weterman et al,
1992, 1993). Protein expression has been found to be increased at
the invading fronts of colorectal adenocarcinomas, and may be
involved in the invasion process (Komatsu et al, 2000). In
astrocytic tumours S100A6 protein expression correlates with
tumour grade (Camby et al, 1999). Recently, S100A6 has been
identified as a differentially expressed gene in pancreatic
adenocarcinomas (Logsdon et al, 2003). Other than one recent
report showing S100A6 expression in B20% of prostatic cancers
arranged on a tissue-microarray (Hsieh et al, 2003), there are no
reports investigating S100A6 expression in benign and malignant
prostate tissues or cell lines. We therefore examined the tissue
expression of S100A6 in benign, malignant and metastatic prostate
tissues and in prostate cancer cell lines. The possible mechanism
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for the absence of expression in prostate cancer cell lines was
investigated by bisulphite modified DNA sequencing of CpG sites
within the S100A6 promoter and 50 upstream sequence of exon 1.
MATERIALS AND METHODS
Tissue specimens
Following local ethics committee approval and informed consent,
tissues were collected from a total of 71 patients, who attended the
Urology clinic at three centres: Academic Urology Unit, University
of Sheffield; CeRePP-EA3104, De´partements d’Urologie, Univer-
site´s Paris or Service d’Anatomie Pathologique, CHU Nancy-
Brabois (France). Paraffin-embedded tissue in blocks from 28
histologically proven cases of organ confined prostate cancer
obtained either by radical prostectomy or Transurethral resection
of prostate (TURP) were collected at the Universite´s Paris. Organ
confined tumours had Gleason scores ranging from 3 to 6 (n¼ 3),
7 (n¼ 13) and 8– 10 (n¼ 12). Four cases of metastatic prostate
cancer in lymph node were collected at the Service d’Anatomie
Pathologique and one case of metastatic prostate cancer in bone
was collected at the University of Sheffield.
Tissue microarrays
For the construction of Tissue Microarrays (TMA), 38 tumour
tissue samples obtained either by radical prostectomy or TURP
were collected at the University of Sheffield. Areas representing
the largest carcinoma as well as areas of normal appearing
epithelium and normal appearing stroma were circled on the
haematoxylin & eosin stained slides. For each area, triplicate
0.6 mm cores were obtained from the circled areas and were
transferred onto recipient paraffin blocks. Tumour areas
sampled generally reflected the final Gleason score for the case
and included low, intermediate and high-grade adenocarcinomas.
In total, 5-mm sections from the array blocks and tissues were cut
for immunohistochemistry.
Prostate cancer cell lines and culture
PC3, Du145 and LNCaP cell lines were obtained from the
American-Type Culture Collection (Manassas, VA, USA). PC-3M,
PC-3M-LN4, LNCaP-LN3 and LNCaP-Pro5 cell lines were kindly
provided by Dr CA Pettaway (University of Texas MD Anderson
Cancer Centre, Houston, TX, USA) (Pettaway et al, 1996). All cell
lines were maintained in RPM1-1640 with 10% foetal calf serum,
glutamine, vitamins, amino-acids and antibiotics.
RNA extraction
RNA was extracted using TRI reagent (Sigma-Aldrich, Dorset,
UK), according to the manufacturer’s instructions. After precipita-
tion the pellet was washed three times with 75% ethanol. All RNA
was quantified spectrophotometrically.
RT–PCR
RNA (2 mg) was reverse transcribed into cDNA using a reverse
transcription kit (Invitrogen), with 250 ng of random primers
according to the manufacturer’s instructions. For S100A6 PCR two
primer pairs were designed using the cDNA sequence of the
Ensembl genome browser (Ensembl gene i.d. ENSG00000160670).
The sequence of the forward and reverse primer pairs were:
S100A6F1 GTAAACCGCGAATGTGCGTTGT (exon 1)
S100A6R1 GAGTACTTGTGGAAGATGGCCA (exon 2)
S100A6F2 AGCTGAAGGAGCTGATCCAGAA (exon 2)
S100A6R2 CCCTTGAGGGCTTCATTGTAGA (exon 3)
GAPDH PCR was performed to test RNA integrity and as a
loading control. Primer sequences were
GAPDHF GAAGGTGAAGGTCGGAGTC
GAPDHR GAAGATGGTGATGGGATTTC
All primers were synthesised by MWG-Biotech (UK). RT–PCR
was performed using 200 ng of each primer in 20 ml volumes.
Touch down thermocycling was performed using the following
annealing temperatures, three cycles each of 651C for 30 s, 621C for
30 s, 591C for 30 s then 30 cycles of 561C for 1 min. All denaturation
steps were 941C for 30 s and all extension steps were 721C for 30 s.
PCR controls consisted of nontranscribed total RNA and water.
Amplified products were separated on 2.5% agarose gels contain-
ing ethidium bromide.
Immunohistochemistry
Immunohistochemistry was performed essentially as previously
described with the following modifications (Rehman et al, 1996).
Nonspecific sites were blocked using 1 Casein (Vector
laboratories, Peterborough, UK) in 0.5 M Tris-buffered saline
(TBS), 2 mM CaCl2, 0.05% Tween 20, pH 7.5. Sections were
incubated for 1 h with rabbit anti-S100A6 polyclonal antibody at a
1 : 1000 dilution (Cat. No. A5115, Dako, Cambs, UK) or Mouse
monoclonal anti-S100A6 antibody (Cat. No. S5049, Sigma-Aldrich,
Dorset, UK) at a 1 : 2000 dilution in 1/4 Casein in 0.5 M TBS,
2 mM CaCl2, 0.012% Tween 20, pH 7.5. Secondary antibodies were
either biotinylated Goat anti-rabbit (1 : 400 dilution) (Vector
laboratories) or biotinylated rabbit anti-mouse (1 : 400 dilution)
(Dako). Cytokeratin 5 and 18 immunostaining was performed
using mouse monoclonal antibodies (NCL-L-CK5 and NCL-CK18,
Novocastra laboratories, Newcastle, UK). S100B immunostaining
was performed using the monoclonal mouse anti-S100B antibody
(Cat No. M7221, Dako), at a 1 : 30 dilution. For immunostaining of
cell lines, cells fixed with 4% paraformaldehdye/PBS were first
treated with hot sodium citrate pH 6.0 for 15 min, and the staining
performed as described above. Negative controls were included for
most tissues and included omission of primary antibody. All
immunostained tissues were scored by an expert histopathologist
(SSC).
Western blotting
Protein was extracted from all seven cell lines using the
mammalian cell lysis kit (Sigma-Aldrich) and the NER-PER kit
(Pierce Biotechnology), according to the manufacturer’s instruc-
tions. Protein extracts (20mg each) were run on 12% SDS-Tris-
glycine gels and blotted onto immobilon PVDF transfer mem-
branes (Millipore, Watford, UK) for 1 h at 65 V. Blots were then
blocked by 5% non-fat milk for 1 h, incubated with a 1 : 2000
dilution of the anti-S100A6 polyclonal antibody (Cat No. A5115,
Dako), overnight at 41C. After incubation with secondary
peroxidase conjugated horse anti-rabbit antibody at a 1 : 30 000
dilution (Cat No. NA934 Amersham Biosciences, Bucks, UK), the
membranes were developed by ECL Advanced Western blotting
detection kit (Amersham Biosciences) for X-ray film exposure.
Molecular weight markers used were the See blue plus 2 prestained
standards (Invitrogen).
5-Azacytidine treatment
LNCaP cells were cultured in RPMI-1640 medium as described
above for 2 days in 12-well plates. A final concentration of 1 or
5 mM of freshly prepared 5-azacytidine (Sigma-Aldrich) was added
to the culture medium. After 5 days of treatment, RNA was isolated
using TRI reagent as described above.
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Bisulphite modified DNA sequencing and primer design
The methylation status of the S100A6 gene (promoter region and 50
upstream region of exon 1) was investigated in the S100A6
negative cell lines and in the Du145 cell line, by sequencing of
bisulphite modified DNA (Herman et al, 1996). To design
sequencing primers an appropriate area of the S100A6 promoter
and exon 1 was identified using the published human S100A6
sequence (Gene bank accession number; J02763), and the
MethPrimer design programme (http://itsa.ucsf.edu/~urolab/
methprimer/). The bisulphite modified sense primer sequence
was (IRD 800 labelled) 50 CTCCCCCTATCTCCTCTAAAATAAC 30,
which corresponds to position 1084 to 1109 (designating the
ATG of the translational start site as 0). The bisulphite modified
antisense primer was (IRD 700 labelled) 50 TGGGGGAGTTTAG-
TAGTGTTTATTG 30, which corresponds to position 842 to
867. This 267 bp fragment encompassed the promoter region and
the first 41 nucleotides 50 of exon 1. Genomic DNA was extracted
by a standard phenol–chloroform method. In total, 1 mg of
DNA was treated with sodium bisulphite for 16 h, using the
CpGenome kit (Serologicals, UK), according to the manufacturer’s
instructions. After purification, a 2 ml aliquot was used for
sequencing using the EXCEL II sequencing kit-LC (Epicentre
technologies), according to the manufacturer’s instructions.
Sequencing was performed in both the forward and reverse
direction. The sequencing PCR products were resolved on an
automated sequencer (LICOR) and aligned using the Sequencher
programme.
RESULTS
S100A6 staining in benign prostate tissue
Immunostaining for S100A6 showed that in all 66 cases of benign
epithelium adjacent to prostatic adenocarcinoma, the staining was
seen to be intense in the nuclei and cytoplasm of basal cells, with
luminal cells showing an absence of staining. Overall, the staining
pattern was seen as a single layer of stained cells within the typical
two-layered architecture (Figure 1A and B). Many of the specimens
in blocks showed foci of basal cell proliferations. These are benign
lesions where the basal cells have proliferated to become multi-
layered. S100A6 immunostaining showed intense staining in all
basal cell layers with the single layer of luminal cells showing an
absence of staining (Figure 1C). In all cases absent or weak-
moderate staining was seen in the smooth muscle cells within the
benign stroma (Figure 1A and B).
S100A6 staining in prostate cancer and metastatic lesions
In contrast to the intense expression seen in the basal cell layer of
benign glands, a complete loss of S100A6 staining was seen in all
66 cases of adenocarcinomas, regardless of Gleason score
(Figure 1D). Absent staining was seen in all five cases of metastatic
cancer (Figure 1E and F).
S100A6 staining in high-grade prostatic intraepithelial
neoplasia
In 10 cases of adenocarcinoma, we examined 10 lesions of high-
grade prostatic intraepithelial neoplasia (PIN) chosen at random.
High-grade PIN lesions consist of architecturally benign prostatic
acini lined by cytologically atypical cells in which the basal
cell layer may show some disruption (Bostwick et al, 1997).
S100A6 immunostaining was found to be absent in three cases of
PIN where the basal cell layer was disrupted (Figure 1G, and
was found to be present in the basal cells of the seven cases of
high-grade PIN where an intact basal cell layer was present
(Figure 1H).
Comparison of S100A6 staining with cytokeratin 5 and 18
To compare the S100A6 staining pattern with that of cytokeratin 5
and cytokeratin 18, tissues arranged in a TMA, comprising of 19
cases of matched adenocarcinoma, benign epithelium and benign
stroma were serially cut and immunostained for cytokeratin 5 (a
marker of prostate basal cells), or cytokeratin 18 (a marker for
benign luminal cells), which is also expressed in malignant cells
(Freeman et al, 2002). As expected, in all cases of benign
epithelium intense cytokeratin 5 immunostaining was seen in the
basal cell layer, with an absence of staining in the luminal cells
(Figure 2A), and in all cases this staining pattern was identical to
Figure 1 S100A6 immunostaining in benign, malignant, metastatic
prostate and high-grade PIN samples. (A) Note the intense staining of
the basal cells within the epithelium, seen as a single continuously stained
cell layer ( 200 magnification). (B) Higher magnification shows intense
staining in the cytoplasm and nuclei of basal cells but an absence of staining
in luminal cells ( 400). (C) Staining within an area of basal cell
proliferation ( 400). Note the intense staining in the hyperproliferative
basal cells, with the luminal cells showing absent staining. (D) Adenocarci-
noma showing absent S100A6 expression within the malignant cells, but
intense expression in basal cells of benign glands ( 200). Absent staining
of metastatic cells was seen in (E) bone and (F) lymph node metastasis
( 400). (G) A case of high-grade PIN with a disrupted basal cell layer
showing absent staining ( 400). (H) A case of high-grade PIN with an
intact basal cell layer, showing intense S100A6 staining within the basal cells
( 400).
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the staining pattern seen with S100A6 (Figure 2B). In cases where
weak-moderate S100A6 staining was seen in the smooth muscle
cells of the stroma, this was not seen with cytokeratin 5 (Figures 2A
and B). As expected, intense cytokeratin 18 immunostaining was
seen in the luminal cells of benign epithelium and malignant cells
(Figure 2C). Staining of serial sections showed that the benign
luminal cells and malignant cells stained with cytokeratin 18 were
unstained for S100A6 (Figures 2C and D).
To confirm the S100A6 immunostaining pattern seen using the
polyclonal anti-S100A6 antibody (Dako), we immunostained serial
sections of tissues in blocks and in the TMA, with a mouse
monoclonal anti-S100A6 antibody (Sigma). Concordant staining
patterns were seen in all cases. However, some variation in the
intensity of staining of the stromal compartment was seen between
the two antibodies, with the monoclonal antibody showing slightly
less staining of the stromal compartment (data not shown).
S100A6 expression in prostate cancer cell lines
S100A6 expression was investigated by Western blotting in all
seven cell lines using the anti-S100A6 polyclonal antibody. Protein
expression was seen in Du145, PC3, PC-3M, PC-3M-LN4 cell lines
as a single B10 kDa band, thus confirming the specificity of the
antibody used. However, protein expression was absent in the
LNCaP, LNCaP-LN3, LNCaP-Pro5 cell lines. Figure 3 shows
Western blotting data from representative cell lines (Du145,
LNCaP and PC3). These data were confirmed using two different
protein extraction protocols. To further confirm the expression of
S100A6 in cell lines, we performed immunocytochemistry on
Du145, PC3 and LNCaP cell lines. Cytoplasmic protein expression
was seen in both Du145 and PC3 cells with weak expression in the
nucleus (data not shown). LNCaP cells as expected showed a
complete absence of S100A6 expression.
To confirm the protein expression status in the cell lines, we
performed RT–PCR using two separate PCR primer pairs (S100A6
F1/R1 and S100A6 F2/R2), on RNA extracted from all seven cell
lines. Using both primer sets, S100A6 mRNA expression was
detected in Du145, PC3, PC-3M, PC-3M-LN4 cells, as seen by the
correct sized PCR products, but was absent/very weak in the
LNCaP, LNCaP-LN3 and LNCaP-Pro5 cells. Results using the
S100A6 F2/R2 primer pair for representative cell lines (Du145,
LNCaP and PC3) are shown (Figure 4), but identical results were
seen using the S100A6 F1/R1 primer pair (not shown).
S100B is not expressed in prostate
In neuronal cell lines it has been shown that S100B may form
heterodimers with S100A6 and that S100B protein expression is co-
localised with S100A6 (Deloulme et al, 2000), we therefore
performed immunostaining for S100B in 20 cases of organ
confined prostatic adenocarcinoma with adjacent benign epithe-
lium. S100B expression was completely absent in all cases of
benign and malignant tissues. Melanoma samples included as
positive controls showed intense S100B expression within the
malignant cells (data not shown).
S100A6 mRNA is re-expressed following 5-azacytidine
treatment
Previous studies have shown an inverse correlation between
expression of S100A6 and methylation in human keratinocytes and
fibroblasts (Elder and Zhao, 2002), we therefore investigated
whether this could be the mechanism of silencing in LNCaP cells.
Cells were treated with 5-Azacytidine for 5 days using two doses: 1
and 5 mM. S100A6 mRNA expression was reactivated in LNCaP cells
following treatment with both doses and was seen using both
primer sets. Data using primer pair S100A6F2/R2 are shown
(Figure 4, lanes 5 and 6).
CpG sites within the S100A6 promoter and exon 1 are
methylated in prostate cancer cell lines
In view of the above results, we hypothesised that CpG methylation
may underlie the absence of S100A6 protein expression in the
LNCaP, LNCaP-LN3 and LNCaP-Pro5 cell lines. Bisulphite
modified DNA sequencing of a region of the S100A6 promoter
and 50 upstream region of exon 1 in LNCaP, LNCaP-LN3 and
Figure 2 Comparison of S100A6 immunostaining with cytokeratin 5 and
cytokeratin 18 immunostaining ( 100 magnification). (A) and (B) are
serial sections of benign tissue stained with (A) cytokeratin 5 or (B)
S100A6. Note that the staining patterns are similar with intense staining of
the basal cell layer. In (B), note the weak-moderate staining of the muscle
cells within the stroma. (C) and (D) are serial sections of adenocarcinoma
stained with (C) cytokeratin 18 or (D) S100A6. Note that the cytokeratin
18 positive cells are not stained for S100A6. Basal cells of benign glands
adjacent to carcinoma are stained for S100A6 (D).
Figure 3 Western blot of S100A6, using the polyclonal anti-S100A6
antibody (Dako) on lysates from prostate cancer cell lines. Lane 1. Du145;
lane 2, LNCaP; lane 3, PC3. Note the protein expression in Du145 and
PC3 cells, seen as anB10 kDa band, but its absence in the LNCaP cell line.
Figure 4 RT–PCR of S100A6 using the S100A6 F2/R2 primers ran on a
2.5% agarose/ethidium bromide gel. S100A6 mRNA expression can be
seen in lane 1 (Du145), lane 2 (PC3), but not in lane 3 (LNCaP) or lane 4
(using a two-fold excess of LNCaP cDNA). Treatment of LNCaP cells with
5-Azacytidine caused re-expression of S100A6 mRNA using two different
doses, lane 5 (1 mM) and lane 6 (5 mM). Nontranscribed total RNA or water
used as negative controls showed an absence of PCR product (not shown).
GAPDH was used as a loading control in each case and to check RNA
integrity.
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LNCaP-Pro5 cell lines identified sites of CpG methylation, which
were unmethylated in the Du145 cell line (Figure 5).
DISCUSSION
Previous studies have shown that loss of Annexins and GST-pi are
among the most common alterations occurring in prostate cancer,
with the frequency of loss approaching 100% (Lee et al, 1994;
Paweletz et al, 2000; Chetcuti et al, 2001). This mechanism of loss
is thought to involve hypermethylation, suggesting that epigenetic
mechanisms may play a significant role in the development of
prostate cancer.
Annexins belong to one of the three main family of calcium-
binding proteins. The other family of calcium binding proteins are
the EF type and include the S100 proteins, such as S100B and
S100A6 (Schafer and Heizmann, 1996; Heizmann et al, 2002;
Donato, 2003). The third family comprises the endoplasmic
reticulum proteins, such as calreticulin (Michalak et al, 2002).
Evidence exists for interactions between two different family
members such as Annexin II and S100A6 and between S100B and
S100A6 (Zeng et al, 1993; Kuo et al, 1997; Deloulme et al, 2000).
The human S100A6 gene is located on chromosome 1q21, and
the protein product has been implicated in growth and differentia-
tion as well as in a variety of human cancers (Calabretta et al, 1986;
Weterman et al, 1992; Weterman et al, 1993). To our knowledge
there is only one recent report investigating the tissue expression
of S100A6 in prostatic adenocarcinoma, which showed thatB20%
of the cases arranged on a TMA had S100A6 expression (Hsieh
et al, 2003). However, the limitations of this study are that no cases
of benign tissues were studied and the distribution of staining in
different cell types was not described, that is, no distinction
between luminal or basal cells was made. Given the results of
previous studies showing S100A6 expression to be increased in all
cancers as well as the correlation between expression and
malignant transformation and invasion, our finding of loss of
S100A6 expression in all adenocarcinomas studied was unex-
pected. The frequency of S100A6 loss we observed in our series of
adenocarcinomas is comparable to the frequency of loss reported
for Annexin I and II. Thus, loss of expression of proteins belonging
to the calcium-binding protein family is among the most frequent
events in prostate cancer development.
The finding of S100A6 loss of expression in a significant
proportion of high-grade PIN lesions as well as in all cases of
adenocarcinoma, regardless of Gleason score and in metastatic
lesions, suggests that loss of expression occurs at an early stage of
prostate tumour development and that loss of expression is
maintained throughout tumour progression. In addition, this loss
of expression was related to the loss of the basal cell phenotype in
high-grade PIN and cancer.
Analysis of human prostate cancer cell lines showed expression
of S100A6 protein and mRNA in Du145 (derived from metastatic
prostate in the brain), PC3 (derived from metastatic prostate in the
bone), PC-3M and PC-3M-LN4 (metastatic variants of PC3),
whereas the LNCaP cell line (derived from a lymph node
metastasis) and LNCaP-LN3 and LNCaP-Pro5 cell lines (metastatic
variants of LNCaP) (Pettaway et al, 1996) showed an absence of
protein and mRNA. Although, the absence of S100A6 expression
seen in all tumours was confirmed in the LNCaP cell line and its
variants, other metastatic cell lines such as Du145 and PC3 (and its
variants), were shown to express S100A6. The reason(s) for the
differences in S100A6 expression seen between the human
metastatic tissues and certain cell lines is not known, but it is
possible that re-expression could have occurred at some point
during the establishing of the cell lines. Nevertheless, the finding of
S100A6 expression in some prostate cancer cell lines but not others
provides a useful tool to further understand the mechanism(s)
involved in regulating S100A6 expression.
The pattern of S100A6 immunostaining seen in benign prostate
epithelium was similar to the pattern seen for cytokeratin 5 and
that reported for p63 and 34bE12 (a cocktail of cytokeratins),
which are markers of prostate basal cells (Parsons et al, 2001;
Freeman et al, 2002). In all cases of adenocarcinoma studied, loss
of expression of both S100A6 and cytokeratin 5 was seen in the
malignant cells. This frequency of loss is similar to the frequency
of loss (B95%) reported for p63 in prostate cancer (Parsons et al,
2001). Therefore, S100A6 immunohistochemistry could represent a
novel marker for basal cells in the benign prostate and its absence
in malignant cells may be useful as an adjuvant method to p63 and
34bE12 immunostaining to facilitate the pathological diagnosis of
prostate cancer.
The loss of expression seen in the malignant cells was confirmed
using two commercially available antibodies, that is, a mouse
monoclonal antibody (Sigma) and rabbit polyclonal antibody
(Dako). Both antibodies showed identical staining patterns, using
serial sections, although the monoclonal antibody showed slightly
reduced staining in the stromal compartment. The S100A6
polyclonal antibody was shown to be specific for S100A6, by the
finding of a single band of the correct molecular size (B10 kDa) in
Du145, PC3, PC-3M and PC-3M-LN4 cell lines. In addition, the
absence of protein in LNCaP cells was very unlikely to be due to
proteolytic cleavage since no low molecular weight bands were
seen on the Western blots.
Since yeast two-hybrid experiments have shown S100A6 to
interact with S100B and co-localise in astrocytoma cells (Deloulme
et al, 2000), we investigated the expression of both S100A6 and
S100B in serial sections of prostatic adenocarcinoma of various
Gleason scores and adjacent benign epithelium. We found no
evidence of S100B protein expression in the prostate whereas
Figure 5 S100A6 DNA sequence of prostate cancer cell lines. (A)
Sequence of the 50 upstream region of exon 1, which was investigated
(Gene bank Accession number J02763). The two CpG sites are shown in
bold (B) Chromatographs showing S100A6 exon 1 sequence following
bisulphite modification of DNA from prostate cancer cell lines. Du145
showed an absence of methylation as seen by the conversion of all the G
residues to A residues. Methylation at the two CpG sites (arrows) can be
seen in the LNCaP, LNCaP-LN3 and LNCaP-Pro5 cell lines, since the G
residues at these sites were not converted, but remained as G residues.
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intense expression was seen in the malignant melanoma cases used
as positive controls (data not shown). This suggests that in
contrast to previous studies, S100A6 is not co-expressed with
S100B and that S100B is unlikely to play a role in the normal
function of S100A6 in the prostate.
As the mechanism of S100A6 loss of expression has been
correlated with DNA methylation in human keratinocytes and
fibroblasts (Elder and Zhao, 2002), we investigated the mechanism
of S100A6 silencing in the LNCaP cell line using the drug 5-
Azacytidine. 5-Azacytidine is a DNA methylation inhibitor that
effectively inactivates the DNA methyltransferase enzyme. Several
in vitro and in vivo studies have reported that 5-Azacytidine can
cause hypomethylation and reverse the epigenetic silencing of
tumour suppressor genes in tumour cell lines (Bender et al, 1998;
Bovenzi et al, 1999). Our finding that S100A6 mRNA could be re-
activated following treatment of cells with 5-Azacytidine suggested
that hypermethylation could be the mechanism for silencing of the
S100A6 gene. However, more significantly sequencing of bisulphite
modified DNA in LNCaP, LNCaP-LN3 and LNCaP-Pro5 cell lines
showed that CpG methylation was present, but was not present in
Du145 cells which showed high expression of S100A6 protein.
In summary, we have shown intense S100A6 expression in the
basal cells of benign prostate epithelium. Loss of expression was
seen in high-grade PIN, all grades of adenocarcinoma, all
metastatic prostate lesions and in the LNCaP prostate cancer
derived cell line. The high frequency of loss of expression parallels
the frequency of loss seen in other calcium-binding proteins such
as Annexin I and II. The pattern of S100A6 expression in benign
epithelium and adenocarcinomas is similar to that of cytokeratin 5
and that reported for p63 and 34bE12, and therefore has the
potential to be used as an adjuvant to these markers in the
diagnosis of prostate cancer. The mechanism underlying the loss
of expression appears to involve methylation of CpG sites within
the promoter region and exon 1. Further studies regarding the
expression of S100A6 in prostate cancer and other tumours are
clearly warranted.
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